Special Issue

Clinical Applications of Biospectroscopy and Imaging

Message from the Guest Editor

Biospectroscopy involves an emerging inter-disciplinary approach with the potential to revolutionise healthcare diagnosis and screening. The potential for application in clinical arenas ranging from point-of-care primary or triage settings to the implementation of an intraoperative tool to a more complex imaging modality is vast. The range of clinical applications includes, but is not limited to, cancer diagnosis or imaging, characterisation of neurodegenerative disease, bone integrity analysis, antibiotic resistance in bacteria, and regenerative medicine. In various settings and requirements, spectrochemical methods may be employed that range from FTIR to Raman spectroscopy. This then leads to the necessity for the appropriate handling of spectral-derived datasets, be it for exploratory analysis, classification, feature extraction for prediction or imaging. Such complex inter-disciplinarity requires cross-talk between experts in different fields of expertise. In this Special Issue, the current knowledge as well as future perspectives in the contributing fields of biospectroscopy approaches in screening, diagnosis, and imaging in a range of clinical settings will be presented.

Guest Editor

Prof. Dr. Francis L. Martin

Department of Cellular Pathology, Blackpool Teaching Hospitals NHS Foundation Trust, Whinney Heys Road, Blackpool FY3 8NR, UK

Deadline for manuscript submissions

25 February 2025



Journal of Personalized Medicine

an Open Access Journal by MDPI

Impact Factor 3.0 CiteScore 4.1 Indexed in PubMed



mdpi.com/si/162631

Journal of Personalized Medicine MDPI, Grosspeteranlage 5 4052 Basel, Switzerland Tel: +41 61 683 77 34 jpm@mdpi.com

mdpi.com/journal/

<u>jpm</u>





Journal of Personalized Medicine

an Open Access Journal by MDPI

Impact Factor 3.0 CiteScore 4.1 Indexed in PubMed



About the Journal

Message from the Editor-in-Chief

Journal of Personalized Medicine (JPM; ISSN 2075-4426) is an international, open access journal aimed at bringing all aspects of personalized medicine to one platform. JPM publishes cutting edge, innovative preclinical and translational scientific research and technologies related to personalized medicine (e.g., precision medicine, pharmacogenomics/proteomics, systems biology, 'omics association analysis). JPM is covered in Scopus, the Science Citation Index Expanded (SCIE), PubMed, PMC, Embase, and other databases.

Editor-in-Chief

Prof. Dr. David Alan Rizzieri

- 1. Novant Health Cancer Institute, Winston-Salem, NC 27103, USA
- 2. Division of Hematologic Malignancies and Cellular Therapy, Duke University, Durham, NC 27710, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC. Embase, and other databases.

Journal Rank:

JCR - Q1 (Medicine, General and Internal) / CiteScore - Q2 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 16.7 days after submission; acceptance to publication is undertaken in 2.5 days (median values for papers published in this journal in the first half of 2024).

